Physician profile
Gary Sowinski
NPI 1992228258
$928.90
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $903 · 2022: $26.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $215.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.84 | 2021-2022 | |
| Allergan, INC. | $85.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $73.27 | 2021 | |
| Boston Scientific Corporation | $56.24 | 2021-2022 | |
| Nevro Corp. | $55.53 | 2021 | |
| Scilex Pharmaceuticals INC. | $48.86 | 2021 | |
| Almatica Pharma LLC | $36.24 | 2021 | |
| Pfizer INC. | $35.01 | 2021 | |
| Arbor Pharmaceuticals, INC. | $30.51 | 2021 | |
| Biodelivery Sciences International, INC. | $25.84 | 2021 | |
| Abbvie INC. | $18.88 | 2021 | |
| Ibsa Pharma INC. | $15.91 | 2021 | |
| Medtronic, INC. | $14.75 | 2021 | |
| Tersera Therapeutics LLC | $13.07 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $13.06 | 2021 | |
| West Therapeutics Development, LLC | $12.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Sowinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.